Oaklander welcomed the news of the approval of the new vaccine, saying that more adults should be vaccinated against shingles. In the United States alone, there are an estimated 1 million cases of shingles a year, and one in three people can expected to develop the condition during their lifetime.
6 brokerages have issued twelve-month price objectives for Arbutus Biopharma Corp's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Arbutus Biopharma Corp's stock price to reach $7.00 in the next year.
Investors may be tracking sell-side analyst opinions on shares of Array BioPharma Inc. (NASDAQ:ARRY). According to analysts polled by Zacks Research, the current consensus target price is $15.56. Analysts and financial institutions may use different methods to value a particular stock. Because of the use of alternate methods, individual price targets may be widely varied. Viewing the consensus target price can help provide a general sense of where the sell-side sees the stock heading in the future.